Skin Prick Test of KeraStat® Cream

NCT ID: NCT04058054

Last Updated: 2022-11-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-07-29
• Study Completion Date: 2019-08-02

Brief Summary

To evaluate the potential for a humoral reaction to KeraStat Cream compared to a predicate device using the skin prick test.

Detailed Description

Study Overview:

Study Periods:

The length of study participation for a subject is about 2-3 days depending on availability for the final site check. There are two skin prick site checks during the course of Day 1 with a final follow up between Days 2 and 3.

Study Evaluations:

Initial screening (Screening Visit; Visit 1) will be performed on the day of the Skin Prick Test (SPT) administration and will include obtaining demographic information, brief medical history, and abbreviated physical exam.

On Day 1 (Visit 1) the SPT will be performed on the infrascapular region of the back to the right of the midline. Test articles will include the subject device (KeraStat Cream), predicate devices (KeraStat Gel, Biafine), positive control (histamine), and negative control (saline). Each test article will have a single administration, only the re-test will utilize a triplicate administration. The SPT will be ready for initial reading after approximately 15 minutes (but no sooner than 10 minutes and no longer than 20 minutes) following the final SPT administration in the series. When reading the test, the investigator will note the presence or absence of a wheal at all five sites and will measure the diameter of each wheal present. In order for the SPT to be valid, the wheal at the positive control site must exceed that at the negative control by 4 mm. If the above criteria are not met, the SPT will be repeated in triplicate on the infrascapular region of the back to the left of the midline, following the same protocol. Following the initial reading, the subject will remain at the testing facility.

A second reading will be conducted approximately 6 hours (+/- 15 minutes) after SPT administration on Day 1 (Visit 1). When reading the test, the investigator will note the presence or absence of a wheal at all five sites and will measure the diameter of each wheal present. Subjects are free to leave the clinical site after the second reading. Subjects will be instructed to promptly contact the PI and go to the ER if symptoms of an allergic reaction or shock occur.

Subjects will return to the office one to two days after initial administration for a third test reading (Visit 2). When reading the test, the investigator will note the presence or absence of a wheal in all five sites and will measure the diameter of each wheal present. Each site of test article administration will be measured for a positive reaction. A positive reaction is present when there is a measurable wheal of 3 mm or more, surrounded by a flare. Small wheals are to be confirmed by palpation. A flare alone is disregarded.

Conditions

Hypersensitivity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: SINGLE

Study Groups

KeraStat® Cream

KeraStat® Cream is a non-sterile, non-implantable wound dressing intended to provide a moist environment in the management of a variety of partial thickness dermal wounds.

Group Type: EXPERIMENTAL

KeraStat® Cream

Intervention Type: DEVICE

Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.

KeraStat® Gel

KeraStat® Gel is a sterile, non-implantable water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds.

Group Type: EXPERIMENTAL

KeraStat Gel

Intervention Type: DEVICE

Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.

Biafine

Wound dressing for management of partial and full thickness wounds.

Group Type: EXPERIMENTAL

Biafine

Intervention Type: DEVICE

Administered 0.025 gm of Biafine per subject on day 1 of the study.

Histamine

Histamine is provided as a solution of histamine base (6.0 mg/mL).

Group Type: ACTIVE_COMPARATOR

Histamine

Intervention Type: DRUG

Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.

Saline

Saline (sterile) is provided as a 0.9% NaCl solution.

Group Type: SHAM_COMPARATOR

Saline (0.9% NaCl)

Intervention Type: DRUG

Administered 1 drop of saline per subject on day 1 of the study.

Interventions

KeraStat® Cream

Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.

Intervention Type: DEVICE

KeraStat Gel

Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.

Intervention Type: DEVICE

Biafine

Administered 0.025 gm of Biafine per subject on day 1 of the study.

Intervention Type: DEVICE

Histamine

Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.

Intervention Type: DRUG

Saline (0.9% NaCl)

Administered 1 drop of saline per subject on day 1 of the study.

Intervention Type: DRUG

Other Intervention Names

Sodium Chloride syringe

Eligibility Criteria

Inclusion Criteria

1. Men and women, age 18-65

2. Able to understand the informed consent and provide written informed consent

3. Healthy, unmarked skin at the test area

4. Agreement to avoid consumption of antihistamines until completion of third test reading (Visit 2)

Exclusion Criteria

1. Women who are pregnant, lactating/nursing or plan to become pregnant

2. Presence of skin disease, such as widespread urticaria or eczema

3. Diagnosis of infectious disease

4. Receiving corticosteroids, immunosuppressive agents, radiation or chemotherapy, topical growth factors, anxiolytics, imipramine, phenothiazine, dopamine, phenergen, clonidine, montelukast, immunotherapy, UV light therapy, H-2 antagonist, cyclosporine or any other medication the investigator feels will affect the test within the last month

5. Medical history of hypotension, severe hypertension, vasomotor instability, asthma, autoimmune disease, severe cardiac, pulmonary or renal disease

6. Tattoo in the intrascapular test area

7. History of surgical procedure/skin graft in the intrascapular test area

8. Employee or relative of employee of KeraNetics

9. Consumption of an anti-histamine within 7 days of the screening visit

10. History of hypersensitivity to histamine products

11. Any condition the investigator determines will compromise subject safety or prevent the subject from completing the study

12. Participated in an investigational study within 30 days of the screening visit

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

KeraNetics, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan P Wilson, DO

Role: PRINCIPAL_INVESTIGATOR

PMG Research

Locations

PMG Research, Inc.

Winston-Salem, North Carolina, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

KSCM-CRD-002

Identifier Type: -

Identifier Source: org_study_id